Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a progressive liver disease marked by fat accumulation, inflammation, and fibrosis in the liver. Left untreated, MASH can advance to cirrhosis, liver failure, or hepatocellular carcinoma and has become one of the leading indications for liver transplantation in the United States.
People with MASH have an increased risk of heart attack, stroke, and death. The disease burden is substantial and growing, with the U.S. MASH population projected to reach approximately 27.5 million patients by 2030. There are only two FDA-approved drugs for MASH - Madrigal Pharmaceuticals' Rezdiffra and Novo Nordisk's Wegovy.
For comments and feedback: editorial@rttnews.com